logo
The 28 Biggest U.S. Cities Are Sinking, Satellites Say. Here's Why

The 28 Biggest U.S. Cities Are Sinking, Satellites Say. Here's Why

Forbes14-05-2025

A new study using recent satellite data finds that all cities in the United States with populations ... More of more than 600,000 are sinking — and Houston, Texas, the most.
America's most populous cities are finding themselves on increasingly unstable ground, with data from satellites revealing that 28 major U.S. cities are sinking, according to new research. About 34 million people are potentially affected, about 12% of the population. The culprit is the extraction of water from underground aquifers, many of which crumble and compact in the ground.
The research, published in Nature Cities, revealed that metropolises, including New York, Dallas-Fort Worth, Houston and Seattle have urban areas that are sinking by between two and 10 millimeters per year.
At least 20 percent of the urban area in each of the 28 cities is sinking, the data suggests, though the problem is much more serious in most affected cities, with 25 of the 28 cities having at least 65% of the urban area sinking.
A new study using recent satellite data finds that all cities in the United States with populations ... More of more than 600,000 are sinking to one degree or another.
The 28 cities are Austin, Boston, Charlotte, Chicago, Columbus, Dallas, Denver, Detroit, El Paso, Fort Worth, Houston, Indianapolis, Jacksonville, Las Vegas, Los Angeles, Memphis, Nashville, New York, Oklahoma City, Philadelphia, Phoenix, Portland, San Antonio, San Diego, San Francisco, San Jose, Seattle and Washington, D.C.
It's putting more than 29,000 buildings at risk in high and very high damage risk areas, say the authors, with even a slight shift of the land downward threatening the structural integrity of buildings, roads, bridges and dams.
The research is based upon radar measurements from the Sentinel-1 constellation of satellites.
The research is based upon radar measurements from the Sentinel-1 constellation of satellites that use their Synthetic Aperture Radar instruments to measure land elevation changes in all U.S. cities with populations exceeding 600,000. The data was used to create high-resolution maps of subsidence in the 28 most populous U.S. cities. The same technology is often used to measure changes in sea ice, oil spills and land-use change.
"A lot of small changes will build up over time, magnifying weak spots within urban systems and heighten flood risks," said Leonard Ohenhen, lead author and a former graduate student at Virginia Tech's Earth Observation and Innovation Lab.
The fastest-sinking city is Houston, where more than 12% of its area subsides more than 10 millimeters (about 1/5 inch) per year and some localized spots up to 5 centimeters (2 inches) per year. Two other Texas cities, Fort Worth and Dallas, are not far behind. Some localized fast-sinking zones in other places include areas around New York's LaGuardia Airport and parts of Las Vegas, Washington, D.C. and San Francisco.
There is a similar localized impact in New York, Las Vegas and Washington, D.C. However, New York, Chicago, Seattle, Denver [and five other cities] are sinking by the least amount, at about two millimeters per year.
Much of New York City is slowly sinking, with some hot spots, especially around La Guardia Airport, ... More and parts of Jamaica Bay and Staten Island.
In terms of population density, eight cities (New York, Chicago, Los Angeles, Phoenix, Houston, Philadelphia, San Antonio and Dallas) account for more than 60% of the people living on sinking land. These same eight cities have had more than 90 significant floods since 2000, state the authors, with lowering topography as one of the causes.
The cause, according to the researchers, in 80% of cases is the extraction of groundwater, with fast-growing cities rapidly expanding their extraction of freshwater from aquifers faster than they can be replenished. In Texas, the problem is exacerbated by the pumping of oil and gas, the paper says. 'As cities continue to grow, we will see more cities expand into subsiding regions,' said Ohenhen. 'Over time, this subsidence can produce stresses on infrastructure that will go past their safety limit.'
The authors suggest managing groundwater extraction more carefully, using more resilient buildings and infrastructure, and monitoring more. 'As opposed to just saying it's a problem, we can respond, address, mitigate, adapt,' said Ohenhen. 'We have to move to solutions.'
In 2023, scientists discovered that New York City's over one million buildings — and relentless construction — may be causing the city to subside, exacerbating the risk of future flooding.
Wishing you clear skies and wide eyes.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant
Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant

Geek Tyrant

time24 minutes ago

  • Geek Tyrant

Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant

Laika's adaptation of Susanna Clarke's mind-bending fantasy novel Piranesi just took a major step forward with the hiring of acclaimed screenwriter Dave Kajganich to handle the script. Kajganich, known for his work on Suspiria , Bones and All , and AMC's The Terror , is currently collaborating with some of the most respected directors in the industry, including Barry Jenkins, Ridley Scott, and Edward Berger. Now, he'll bring his talents and skills to Laika's ambitious stop-motion take on Clarke's beloved novel. 'Piranesi changed my soul and is one of the books in all the world, of any era, I most cherish,' Kajganich said in a statement. 'Having Travis' and Susanna's trust in adapting it is something I take as an honor of the highest order. They are two of the loveliest, smartest, and most humane people you can imagine, so all of this is an actual dream coming true for me.' First announced in June 2024, Piranesi will be directed by Laika President & CEO Travis Knight, who previously helmed the Oscar-nominated Kubo and the Two Strings and the upcoming Wildwood . The project marks a return to the studio's roots in stop-motion storytelling, even as they continue branching out into live-action. The story for Piranesi is set in a dreamlike alternative reality, and it follows Piranesi, 'whose house is no ordinary building: its rooms are infinite, its corridors endless, its walls are lined with thousands upon thousands of statues, each one different from all the others. 'Within the labyrinth of halls, an ocean is imprisoned; waves thunder up staircases, rooms are flooded in an instant. But Piranesi is not afraid; he understands the tides as he understands the pattern of the labyrinth itself. He lives to explore the house.' There is one other person in the house, 'a man called The Other, who visits Piranesi twice a week and asks for help with research into A Great and Secret Knowledge. 'But as Piranesi explores, evidence emerges of another person, and a terrible truth begins to unravel, revealing a world beyond the one Piranesi has always known.' Since its release, Clarke's novel has become a literary phenomenon, selling over four million copies and winning the 2021 Women's Prize for Fiction. Its meditative tone, philosophical depth, and strange beauty seem tailor-made for Laika's visual storytelling. Knight previously shared in a statement: ' Piranesi is a treasure, and very dear to me. As a filmmaker, I can scarcely imagine a more joyful experience than wandering through the worlds Susanna dreamed into being. 'She's one of my all-time favorite authors, and with Piranesi , Susanna has created a beautiful, devastating and ultimately life-affirming work of art. I'm humbled that she chose LAIKA as her home.' Kajganich is also working on Brad Pitt's The Riders , he's also scripting Be My Baby , a Ronnie Spector biopic for A24, with Zendaya set to star and Barry Jenkins directing. While Laika continues to push further into live-action—with projects like Atmosphere from Anna Boden and Ryan Fleck, and Crumble from Brian Duffield and producers Phil Lord and Chris Miller, the studio hasn't lost sight of what made them a fan favorite in the first place: bold, stylized stop-motion animation that tell stories with emotional weight. Source: Deadline

Taletrectinib Approved for NSCLC
Taletrectinib Approved for NSCLC

Medscape

time44 minutes ago

  • Medscape

Taletrectinib Approved for NSCLC

The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to

Mia Goth Teases Guillermo del Toro's FRANKENSTEIN: 'People Are Going to Love How Epic it Is" — GeekTyrant
Mia Goth Teases Guillermo del Toro's FRANKENSTEIN: 'People Are Going to Love How Epic it Is" — GeekTyrant

Geek Tyrant

time3 hours ago

  • Geek Tyrant

Mia Goth Teases Guillermo del Toro's FRANKENSTEIN: 'People Are Going to Love How Epic it Is" — GeekTyrant

Guillermo del Toro's long-gestating Frankenstein is finally happening, and if you've been waiting for a version that honors the emotional weight and gothic grandeur of Mary Shelley's original novel, Mia Goth says you're in for something special. Goth, who plays Elizabeth Lavenza in the film, shared some insight during a red carpet chat with Entertainment Tonight at Netflix's TUDUM 2025 event. Her comments tease a film that is dark and dramatic, but also deeply human and visually massive. 'I think people are going to love how epic it is, and the scale of it, it's such a feast. But I think they will also be incredibly moved by it and maybe surprised by how much heart went into this. It's a lifelong project for Guillermo.' Del Toro's passion for Frankenstein is strong. Back in 2007, he said that he 'would kill to make' a faithful 'Miltonian tragedy' version of Shelley's novel. He's been dreaming of it for years, and now, thanks to Netflix, it's finally coming. The cast features Jacob Elordi takes on the iconic role of the monster, a transformation that left Goth floored: she says she was 'totally amazed' and 'just in awe.' Elordi is stepping into the shoes of one of horror's most misunderstood figures, and it sounds like he's doing so with style. Meanwhile, Oscar Isaac plays Victor Frankenstein, and Christoph Waltz appears in an as-yet-unnamed but reportedly key role. While Frankenstein has been adapted countless times over the last century, from Karloff's legendary performance to more stylized or sci-fi-heavy interpretations, this version promises a return to the emotional and philosophical core of Shelley's 1818 novel. Goth's comments on the film's emphasis on heart, is what separates Del Toro's monster tales from the rest… his creatures are rarely just creatures. They're metaphors, they're misunderstood, and they're always more than they appear. Frankenstein is set to premiere on Netflix in November 2025, and I'm incredibly excited about seeing Del Toro's vision for this story.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store